@article{JTD13208,
author = {Mohammed A. Chamsi-Pasha and Stephen H. Little and Michael J. Reardon},
title = {The use of transcatheter mitral valve system: can we make mitral regurgitation better again?},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {5},
year = {2017},
keywords = {},
abstract = {Percutaneous treatments of valvular heart disease have evolved over the past two decades. These “minimally invasive” procedures are attractive alternatives to surgery for a growing high-risk population with multiple comorbidities. In 2002, Cribier et al. (1) performed the first transcatheter aortic valve implantation (TAVI) in a patient with aortic stenosis. Currently, TAVI has become a common procedure for high or prohibitive surgical risk patient and is moving rapidly into intermediate risk patients, with over 250,000 devices implanted worldwide.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/13208}
}